Halozyme Therapeutics, Inc. (HALO)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Halozyme Therapeutics, Inc. (HALO)
Go deeper and ask any question about HALO
Company Performance
Current Price
as of Sep 13, 2024$62.30
P/E Ratio
24.15
Market Cap
$7.89B
Description
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Metrics
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerHALO
- Price$62.3+2.91%
Trading Information
- Market Cap$7.89B
- Float98.91%
- Average Daily Volume (1m)1,185,095
- Average Daily Volume (3m)1,287,788
- EPS$2.62
Company
- Revenue$873.30M
- Rev Growth (1yr)4.67%
- Net Income$93.24M
- Gross Margin75.20%
- EBITDA Margin59.47%
- EBITDA$137.60M
- EV$7.77B
- EV/Revenue8.90
- P/E24.15
- P/S9.22
Documents
SEC Filings
Earnings Calls
Factset Street Account
Wikipedia